Sentinel lymph node biopsy for breast cancer

Richard J Bold, M. Schlieman, B. N. Fahy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Sentinel lymph node biopsy (SLNB) is an emerging surgical technique to improve lymph node staging for breast cancer. Despite the rapid development of this technique, there remain aspects of SLNB that need to be further defined to provide a standardized approach. Variables, including patient selection, technical details for the performance of SLNB, extent of pathologic evaluation of the sentinel lymph node, and the impact of micrometastases, are areas of controversy. This paper reviews the controversies and discusses available data as well as personal experience and opinion.

Original languageEnglish (US)
Pages (from-to)347-357
Number of pages11
JournalCancer Biotherapy and Radiopharmaceuticals
Volume16
Issue number5
StatePublished - 2001

Fingerprint

Sentinel Lymph Node Biopsy
Breast Neoplasms
Neoplasm Micrometastasis
Patient Selection
Lymph Nodes

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Sentinel lymph node biopsy for breast cancer. / Bold, Richard J; Schlieman, M.; Fahy, B. N.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 16, No. 5, 2001, p. 347-357.

Research output: Contribution to journalArticle

Bold, RJ, Schlieman, M & Fahy, BN 2001, 'Sentinel lymph node biopsy for breast cancer', Cancer Biotherapy and Radiopharmaceuticals, vol. 16, no. 5, pp. 347-357.
Bold, Richard J ; Schlieman, M. ; Fahy, B. N. / Sentinel lymph node biopsy for breast cancer. In: Cancer Biotherapy and Radiopharmaceuticals. 2001 ; Vol. 16, No. 5. pp. 347-357.
@article{590455633ca5495eb451a5c5d98ffdc2,
title = "Sentinel lymph node biopsy for breast cancer",
abstract = "Sentinel lymph node biopsy (SLNB) is an emerging surgical technique to improve lymph node staging for breast cancer. Despite the rapid development of this technique, there remain aspects of SLNB that need to be further defined to provide a standardized approach. Variables, including patient selection, technical details for the performance of SLNB, extent of pathologic evaluation of the sentinel lymph node, and the impact of micrometastases, are areas of controversy. This paper reviews the controversies and discusses available data as well as personal experience and opinion.",
author = "Bold, {Richard J} and M. Schlieman and Fahy, {B. N.}",
year = "2001",
language = "English (US)",
volume = "16",
pages = "347--357",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Sentinel lymph node biopsy for breast cancer

AU - Bold, Richard J

AU - Schlieman, M.

AU - Fahy, B. N.

PY - 2001

Y1 - 2001

N2 - Sentinel lymph node biopsy (SLNB) is an emerging surgical technique to improve lymph node staging for breast cancer. Despite the rapid development of this technique, there remain aspects of SLNB that need to be further defined to provide a standardized approach. Variables, including patient selection, technical details for the performance of SLNB, extent of pathologic evaluation of the sentinel lymph node, and the impact of micrometastases, are areas of controversy. This paper reviews the controversies and discusses available data as well as personal experience and opinion.

AB - Sentinel lymph node biopsy (SLNB) is an emerging surgical technique to improve lymph node staging for breast cancer. Despite the rapid development of this technique, there remain aspects of SLNB that need to be further defined to provide a standardized approach. Variables, including patient selection, technical details for the performance of SLNB, extent of pathologic evaluation of the sentinel lymph node, and the impact of micrometastases, are areas of controversy. This paper reviews the controversies and discusses available data as well as personal experience and opinion.

UR - http://www.scopus.com/inward/record.url?scp=0035217908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035217908&partnerID=8YFLogxK

M3 - Article

C2 - 11776752

AN - SCOPUS:0035217908

VL - 16

SP - 347

EP - 357

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 5

ER -